Furthermore, GDF-15 levels have been associated with adverse events in community-dwelling populations and higher risk to develop CVDs in patients with non-CVDs disorders [376,377,378,379,380,381,382,383,384,385], as well as adverse prognosis in patients with ACS [386,387,388,389] and HF [63,318,375,390,391,392]. This evidence concerns the gene GDF15 and hydrops fetalis.